News

Modus Therapeutics Secures Significant Funding to Advance Treatments

Modus Therapeutics Secures Significant Funding to Advance Treatments

Major Funding Boost for Modus Therapeutics

In a significant development, Karolinska Development AB (NASDAQ: KDEV) has announced that Modus Therapeutics, one of its esteemed portfolio companies, has successfully raised SEK 28.3 million through an oversubscribed unit issue. This financing initiative received an impressive subscription rate of 189 percent, which underscores the growing confidence in the company's prospects and its innovative drug candidate, sevuparin, aimed at treating chronic kidney disease.

Details of the Unit Issue

Modus Therapeutics has positioned itself strongly in the marketplace as it executes a unit issue that not only raises substantial capital but also signals strong investor confidence. With a 189 percent subscription rate, the need for any guarantee commitments during this phase has been effectively eliminated, thereby streamlining the funding process.

Allocation of Proceeds

The net proceeds from this successful fundraising effort total SEK 24.4 million. A notable portion of these funds, approximately SEK 5 million, is earmarked to settle outstanding loans from its largest shareholder, Karolinska Development. The remaining funds will predominantly support clinical activities, especially focusing on the ongoing Phase 2 study of sevuparin. Furthermore, these resources, which will also include proceeds from exercising warrants of series TO 2026, are anticipated to sustain the company's financial health up to the end of 2026.

Alan Drvota's Encouraging Remarks

Viktor Drvota, the CEO of Karolinska Development, expressed optimism regarding the oversubscribed rights issue. He emphasized that it represents a vital milestone for Modus Therapeutics, especially in a market environment that poses unique challenges. This success not only reveals the resilience of Modus Therapeutics but also reflects robust support and trust in its clinical advancement efforts.

Ownership Structure and Strategic Focus

Karolinska Development holds a significant stake in Modus Therapeutics, with approximately 66 percent ownership directly and an additional 8 percent indirectly through KDev Investments. This strategic investment ensures that Karolinska Development plays a pivotal role in driving Modus Therapeutics' growth trajectory.

About Karolinska Development

Karolinska Development AB is recognized as a leading Nordic life sciences investment company. Its strategy emphasizes identifying groundbreaking medical innovations within the Nordic region, often pioneered by entrepreneurial teams. By investing in the development of these assets into commercial products, Karolinska Development seeks to enhance the lives of patients while delivering appealing returns to its investors.

Looking Ahead: Future Innovations

The portfolio of Karolinska Development includes eleven companies all dedicated to tackling severe and debilitating diseases through innovative treatments. This approach not only ensures the advancement of life-changing therapies but also supports skilled scientists and management teams dedicated to success.

Connecting with Leadership

For those interested in learning more about Modus Therapeutics or any other endeavors spearheaded by Karolinska Development, the leadership team is readily available. Viktor Drvota, CEO, can be reached at +46 73 982 52 02, while Johan Dighed, General Counsel and Deputy CEO, is available at +46 70 207 48 26.

Frequently Asked Questions

What is the total amount raised by Modus Therapeutics in this funding round?

Modus Therapeutics raised a total of SEK 28.3 million in this unit issue.

What will the funds be used for?

The funds will be used primarily for clinical activities related to the development of the drug candidate sevuparin.

Who is the CEO of Karolinska Development?

The CEO of Karolinska Development is Viktor Drvota.

What percentage of Modus Therapeutics does Karolinska Development own?

Karolinska Development owns approximately 66 percent directly and 8 percent indirectly of Modus Therapeutics.

What is sevuparin?

Sevuparin is a drug candidate developed by Modus Therapeutics intended for the treatment of chronic kidney disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

IEHP's Wellness Center Launch Faces Delay in California

Updated Category News Views 104

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 153

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 211

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 166

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 158

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 0

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 249

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 281

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 139

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading

Top 5 Most Recently Viewed Articles

CNX Resources Reveals Third Quarter Results and Upcoming Call

Updated Category News Views 36

CNX Resources Corporation Financial Update CNX Resources Corporation (NYSE: CNX) is gearing up to announce its financial outcomes for the third quarter of 2024. This announcement is scheduled for 6:45 a.m. Eastern Time on a Thursday morning toward the end of October. During this time, CNX will also share essential materials, including remarks prepared for the quarter,...

Continue Reading
MBZUAI Enhances Research Collaboration with École Polytechnique

Updated Category News Views 183

Strengthening Research Cooperation Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has officially expanded its strategic partnership with École Polytechnique, aiming for a more profound collaboration in artificial intelligence (AI) research. This new Collaborative Research Agreement is a significant step towards enhancing research capabilities in both...

Continue Reading
Projected Growth of Marine Collagen: Key Insights and Trends

Updated Category News Views 152

The Growing Marine Collagen Market The marine collagen market is set to experience significant growth in the coming years. As consumer awareness around health and beauty continues to rise, we see a shift in preference towards marine collagen, thanks to its impressive bioavailability and sustainable sourcing methods. Recent analyses reveal that this sector is predicted to...

Continue Reading
BioLife Solutions Prepares for Q1 2025 Financial Disclosure

Updated Category News Views 144

Exciting Financial Insights Awaiting from BioLife Solutions BioLife Solutions, Inc. (NASDAQ: BLFS) has announced that it will disclose its first quarter 2025 financial results, marking an important update for investors and stakeholders alike. This revelation is set to occur after the market closes, creating anticipation among those closely monitoring the company’s...

Continue Reading
FuboTV Achieves Record Subscriber Growth in North America

Updated Category News Views 174

FuboTV Reports Unprecedented Subscriber Growth FuboTV (NYSE: FUBO) has recently made headlines as it recorded the highest-ever growth in its North American subscriber base. This achievement highlights the company’s potential in the competitive streaming industry. The stock saw a notable increase on the day the company announced its earnings for the third quarter....

Continue Reading